MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Lexicon Pharmaceuticals Inc

Closed

SectorHealthcare

1.28 10.34

Overview

Share price change

24h

Current

Min

1.15

Max

1.32

Key metrics

By Trading Economics

Income

8.5M

-25M

Sales

-25M

1.3M

Profit margin

-2,004.358

Employees

103

EBITDA

4.1M

-26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+239.81% upside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

184M

429M

Previous open

-9.06

Previous close

1.28

News Sentiment

By Acuity

100%

0%

359 / 376 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Lexicon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 lis 2024, 12:42 UTC

Major Market Movers

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

239.81% upside

12 Months Forecast

Average 3.67 USD  239.81%

High 6 USD

Low 1 USD

Based on 3 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

0.6863 / 0.72Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

359 / 376 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.